Cargando…
Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?
The incidence rate and mortality of liver fibrosis caused by various etiologies are high throughout the world. Liver fibrosis, the subsequent cirrhosis and other serious related complications threaten the health of patients and represent a serious medical burden; yet, there is still a lack of approv...
Autores principales: | Chang, Yue, Li, Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438353/ https://www.ncbi.nlm.nih.gov/pubmed/32832403 http://dx.doi.org/10.14218/JCTH.2020.00026 |
Ejemplares similares
-
Antifibrotic Therapies: Will We Ever Get There?
por: Thompson, Alexander James, et al.
Publicado: (2010) -
Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail, Mona H, et al.
Publicado: (2011) -
An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents
por: Rupcic Rubin, Vinka, et al.
Publicado: (2021) -
Are we over-dependent on pharmacotherapy?
por: Kallivayalil, Roy Abraham
Publicado: (2008) -
Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)